Veröffentlichungen
Highlits vom Kongress ASCO 2022 zur Therapie mit CDK4/6-Inhibitoren
Statement Dr. med. Thomas Göhler zur PALOMA-2-Studie: Postmenopausale Frauen mit HR+ / HER2- metastaiertem Brustkrebs ohne Vorbehandlung
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in secondline- and third-line treatment of patients with Her2- negative metastatic breast cancer (PASO)
Juli 2017
- Autoren: Decker Thomas, Overkamp Friedrich, Rösel Siegfried, Nusch Arnold, Göhler Thomas, Indorf Martin, Sahlmann Jörg, Trarbach Tanja
- Institution: Onkologie Ravensburg; Oncologianova GmbH, Recklinghausen; Onkodoc, Güterslo; Practice for Haematology and internal Oncology, Velbert; Oncologic Practice, Dresden; iOMEDICO, Freiburg; Center for Tumor Biology and Integrative Medicine Clinics Wilhelmshaven
- Journal BMC Cancer 2017 (17: 499) / Published online 2017 Jul 25. doi: 10.1186/s12885-017-3492-1
EC-Paclitaxel und Paclitaxel-EC in der primären Therapie des Mammakarzinoms
Juli 2017
- Autoren: M. Konias, Oranienburg; A. Schlichting, Sarstedt; G. Innig, Reihne; C. Spohn, Halle; T. Göhler, Dresden; C. Priebe-Richter, Stadthagen; V. Petersen, Heidenheim; H. Eschenburg, Güstrow; H.-J. Hurtz, Halle; D-T. Baerens, Groß Ilsede; H.-W. Tessen, Goslar
- Senologiekongress Berlin 2017 (Abstract)
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Juni 2017
- Autoren: Eric S Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Yasser Mostafa Kamel, Paul Burgess, Stacey Kalambakas, Frederic Forget
- International Journal of Hematology 2017 (106, pages765–776)
FOLFOX plus Bevacizumab (Bev) vs. FOLFOXIRI plus Bev in advanced Colorectal Cancer (CRC): A randomized Phase II trial (AIO KRK 0209, CHARTA)
Mai 2017
- Autoren: Alexander Stein, Benjamin Garlipp, Christian Junghanß, Malte Leithäuser, Arndt Vogel, Michael Schaefers, Ulrich Kaiser, Heinz-Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Göhler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Jörg Steighardt, Fabian Meinert, Franziska Cygon, Hans-Joachim Schmoll
- Institution: Universitätsklinikum Hamburg-Eppendorf, Germany; Otto von Guericke University Hospital, Magdeburg, Germany; University Hospital, Rostock, Germany; Hannover Medical School, Germany; Onkologische Schwerpunktpraxis, Düsseldorf, Germany; St.Bernward Krankenhaus, Hildesheim, Germany; Klinikum Fulda gAG, Germany; Städtisches Klinikum Dessau, Germany; Germany Division Clinical Oncology, University Hospital, Halle, Germany; Leopoldina Krankenhaus, Schweinfurt, Germany; Urologiepraxis Schkeuditz, Hämato-Onkolische Schwerpunktpraxis Troisdorf, Onkozentrum Gemeinschaftspraxis Dresden, Onkolgische Praxis Bottrop, Charite´ Campus Virchow Klinikum Berlin, Klinikum Magdeburg, University Hospital, Halle, Germany
- DGHO 2016, ESMO 2016, ASCO 2017 (Abstract)
- Journal of Clinical Oncology 2017 (DOI: 10.1200/JCO.2017.35.15_suppl.3533 Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017) 3533-3533)
Lenalidomide Maintenance after Front Line Therapy Substatially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)
Dezember 2016
- Autoren: Anna Maria Fink, Jasmin Bahlo, Robrecht Sandra, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ulrich, Steffen Doerfel, Kirsten Fischer, Clemens Martin Wendtner, Thomas Noesslinger, Paolo Ghia, Francesc Bosch, Arnon P. Kater, Karl-Anton Kreuzer, Hartmut Dohner, Michael Kneba, StephanStilgenbauer, Sebastian Boettcher, Barbara Eichhorst and Michael Hallek
- ASH 2016 (Abstract)
- Bloodjournal 2016 (doi.org/10.1182/blood.V128.22.229.229)